Silexion Therapeutics partners with Evonik to develop advanced siRNA formulation for cancer treatment.

From GlobeNewswire: 2024-12-17 06:30:00

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced a collaboration with Evonik to develop an advanced siRNA formulation for cancer treatment. The formulation, using Evonik’s proprietary microparticle technology, has shown high efficacy in preclinical models targeting KRAS mutations. This collaboration aims to enhance the stability and targeting of SIL-204, Silexion’s next-generation siRNA candidate for KRAS-driven cancers. Silexion remains committed to advancing RNA interference therapies for difficult-to-treat cancers. For more information, visit their website at https://silexion.com. Contact Silexion Therapeutics Corp at [email protected] or ARX Capital Markets Advisors at [email protected].



Read more at GlobeNewswire: Silexion Therapeutics collaborates with Evonik on advanced